Another approach in targeted cancer gene therapy of solid tissues is based on local delivery of NK4 (hepatocyte growth factor antagonist) secreted from an NK4 gene-transduced oral mucosal epithelial cell [37]. The gene discussed is IL32; the disease is cancer.